1 The EIC Accelerator Project
EIC Accelerator Program: An Overview
The EIC Accelerator program, part of the European Innovation Council (EIC), is designed to support small and medium-sized enterprises (SMEs) and startups in Europe, particularly those engaged in deep-tech innovation. The program aims to help these entities develop and scale their groundbreaking technologies, ultimately contributing to the growth of the European economy and enhancing global competitiveness.
Funding Structure
The EIC Accelerator provides a unique blended finance approach, combining grants and equity funding to facilitate the development of innovative projects.
Purpose and Impact
The primary purpose of the EIC Accelerator is to support the growth of innovative companies that are integral to the European deep-tech landscape. By providing financial resources and strategic support, the program helps these businesses navigate the complex process of scaling their operations and bringing innovative solutions to market.
Moreover, the EIC Accelerator plays a critical role in bridging the funding gap that often exists in the early stages of company development. By leveraging public funding, the program encourages private investors to participate, thus creating a robust funding ecosystem conducive to innovation and growth.
Case Study: PCUBE-LAB and NeuroClues
Company Overview: PCUBE-LAB is a Belgian startup that has emerged as a leader in the development of innovative medical devices. The company focuses on transforming the diagnostic process for movement disorders through advanced technology.
Project Overview: The company’s EIC Accelerator project, titled NeuroClues: the clinical must-have for Neurologists, aims to introduce a first-of-its-kind portable eye tracking medical device. This device is designed to bring clinically validated eye movement biomarkers for movement disorders (MDs) into the routine practices of neurologists.
Technology Basics and Background
NeuroClues leverages advanced eye-tracking technology to measure eye movement patterns, which are critical indicators in diagnosing various movement disorders. Movement disorders such as Parkinson's disease, essential tremor, and dystonia can significantly impact a patient's quality of life. Traditional diagnostic methods often rely on subjective assessments, making it challenging to obtain consistent and accurate results.
The technology behind NeuroClues involves sophisticated algorithms that analyze the data captured by high-resolution cameras and sensors embedded in the device. This setup allows for real-time analysis of eye movements, providing neurologists with objective biomarkers that can aid in the diagnosis and monitoring of movement disorders.
Clinical Validation: The device has undergone rigorous clinical trials to ensure its accuracy and reliability. By integrating validated biomarkers into the diagnostic process, NeuroClues aims to improve the speed and reliability of diagnosis, ultimately allowing for earlier intervention and better management of movement disorders.
Conclusion
The EIC Accelerator program serves as a vital resource in the European startup ecosystem, particularly for deep-tech companies like PCUBE-LAB. By offering a combination of grants and equity funding, the program not only supports innovative projects like NeuroClues but also fosters an environment conducive to growth and investment. As the demand for effective diagnostic tools in neurology increases, initiatives like NeuroClues represent the future of clinical practice, promising to enhance the lives of countless individuals affected by movement disorders.
2 The Funding Rounds
Financing Raised and Funding Rounds
Since being selected for EIC Accelerator funding in October 2022, PCUBE-LAB (also known as P3Lab or neuroClues) from Belgium has completed several significant financing rounds:
- Seed Round (November 2021): PCUBE-LAB raised €4.7 million to finalize the development of their neurological diagnostic device and prepare for commercialization in Europe and the US.
- EIC Accelerator Blended Funding (December 2022): The company was awarded a highly competitive blended package by the European Commission:
- €2.5 million grant
- Up to €9 million in equity investment
Timing and Amount of Funding Rounds
| Date | Type | Amount Raised | Purpose |
|---|---|---|---|
| Nov 2021 | Seed | €4.7 million | Finalize product development; prep EU/US market entry |
| Dec 2022 | EIC Accelerator | Grant: €2.5M Equity: up to €9M | Scale-up innovation; regulatory & market readiness |
| Apr 2024 | Pre-Series A | €4.95 million | Regulatory approvals & initial commercial deployment |
</em>EIC Accelerator awards can combine grant with significant equity ("blended finance"), supporting both technology maturation and business growth.
Investor Information
The investors involved reflect a mix of public innovation funds (notably, substantial support from the European Commission via EIC) alongside private capital raised during seed and pre-Series A rounds. Specific private investor names have not been publicly disclosed for these latter rounds as per available data. The board includes individuals like Olivier Legrain, Marie Vidailhet, MD, Diane Lejeune; however, their roles are likely governance/advisory rather than direct venture investors.
PCUBE-LAB remains privately held at this stage.
Company Valuations
No explicit company valuation figures have been published regarding any funding event since winning EIC support or during subsequent private financing rounds. However, given typical deal structures under EIC blended finance—where up to €17.5M can be invested depending on company needs—and comparison with peer deep-tech startups at similar stages, valuations would likely range from tens of millions depending on milestones achieved around regulatory approval and commercialization potential.
Exit Events: IPOs or Acquisitions
As of May 2025:
- There is no record that PCUBE-LAB / P3Lab / neuroClues has pursued an IPO.
- No acquisitions or buyouts involving PCUBE-LAB have been reported.
Sources
- EIC Accelerator October Cut-Off – List of Funded Companies
- PCUBE-LAB – European Commission Portfolio
- Company Overview – neuroClues/P3Lab
- Investors Section – neuroClues
3 The Press Releases
PCUBE-LAB: EIC Accelerator Winner from Belgium
PCUBE-LAB, an innovative company from Belgium, successfully secured funding through the European Innovation Council (EIC) Accelerator in October 2022. This prestigious award acknowledges the company's groundbreaking technology and potential for significant impact in its field.
Technology and Innovation
PCUBE-LAB is recognized for its development of NeuroClues, a first-of-a-kind portable, fast, and easy-to-use eye-tracking medical device designed for neurologists. This technology represents a significant advancement in neurological diagnostics, offering a clinical tool that can enhance patient care and research in neurology.
Partnerships and Funding
While specific partnerships related to PCUBE-LAB are not detailed in available sources, the company's selection for EIC Accelerator funding highlights its potential for collaboration with European innovation networks. The EIC Accelerator provides a combination of grants and investments, supporting companies like PCUBE-LAB in scaling their innovations.
Team Updates and Patents
There is no specific information available regarding team updates or patents filed by PCUBE-LAB following their EIC Accelerator win. However, companies receiving such funding often experience growth and increased visibility, which can lead to further developments in their team and intellectual property portfolio.
Press Releases and Updates
As of the latest available information, there are no specific press releases or blog posts on PCUBE-LAB's website (p3lab.com) directly related to their EIC Accelerator win. However, such announcements are typically made through official channels and might be available on their website or social media platforms.
Conclusion
PCUBE-LAB's achievement in securing EIC Accelerator funding underscores its commitment to innovation and its potential to make a significant impact in the medical technology sector. With its focus on advanced neurological diagnostics, PCUBE-LAB is poised to contribute meaningfully to healthcare advancements.
Sources:
- EIC Accelerator winners and statistics October 2022 - Strata.team
- The European Innovation Council welcomes 78 high potential start-ups and SMEs
- EIC Accelerator 5 October cut-off - European Innovation Council
4 The Technology Advancements
PCUBE-LAB: Current Capabilities and Advancements
PCUBE-LAB, a Belgian med-tech firm based in Louvain-la-Neuve, specializes in neurological diagnostics. Their platform utilizes eye movement biomarkers to aid in the early detection of neurological disorders like Parkinsonian syndromes. The company has made significant strides in advancing its technology, particularly after receiving funding.
Current Capabilities
PCUBE-LAB's core technology is centered around Neuroclues, a patented pupil-frequency tagging technique. This innovative approach helps in the early diagnosis of neurological conditions such as Parkinson's, multiple sclerosis, and Alzheimer's disease. The technology leverages eye tracking to deliver its full potential in clinical practice.
Advancements Since EIC Accelerator Funding
Following the EIC Accelerator funding in October 2022, PCUBE-LAB has continued to progress. In 2022, the company announced a €2.5 million grant and received commitments of up to €9 million in upcoming equity. By 2024, PCUBE-LAB secured a €5 million pre-Series A round to pursue regulatory approvals in Europe and the U.S. and initiate commercial deployment in the U.S..
Technology Improvements and New Features
While specific details about new features are not widely published, the funding and grants suggest ongoing development and refinement of their eye-tracking technology. This includes enhancing the Neuroclues platform for better clinical applications.
Market Demonstration and Trials
There is no publicly available information detailing specific market demonstrations, customer trials, or clinical trials conducted by PCUBE-LAB since the EIC funding. However, their efforts are focused on bringing their technology to European and U.S. markets, which implies ongoing engagement with potential customers and clinical partners.
Patents, Scientific Studies, and Clinical Trials
There is no recent information available regarding new patents filed or scientific studies published by PCUBE-LAB. The company's focus remains on enhancing neurological care through its innovative eye-tracking technology.
Sources
- Pcube-Lab raises $4.75M to advance its eye-tracking technology
- PCUBE-LAB - European Commission
- Company - neuroClues
5 The Partnerships and Customers
PCUBE-LAB, a Belgian company specializing in neurological diagnostics, successfully secured funding through the EIC Accelerator in October 2022. The company's platform focuses on extracting eye movement biomarkers to aid in the early detection of neurological disorders such as Parkinsonian syndromes.Current Partnerships and Customers
As of the latest information, specific details about PCUBE-LAB's partnerships or customers are not widely disclosed. However, the company has been involved in raising significant funding to advance its eye-tracking technology. In 2021, PCUBE-LAB closed a funding round worth $4.75 million, supported by major investment funds like Invest BW SA from Belgium and Graph Ventures LLC from the U.S.. This funding has likely contributed to establishing or strengthening relationships within the medical technology sector, although specific names of customers or partners are not mentioned.
New Partnerships and Customers
There is currently no publicly available information on new partnerships or customers for PCUBE-LAB. The company's focus on neurological diagnostics suggests potential collaborations with research institutions, hospitals, or pharmaceutical companies interested in neurological disorder diagnostics and treatments.
Nature of New Relationships
If PCUBE-LAB were to form new relationships, they would likely involve collaborations with medical research institutions, healthcare providers, or technology companies to enhance its diagnostic capabilities. Such partnerships could help PCUBE-LAB refine its technology, expand its market reach, and improve the accuracy of its diagnostic tools.
Market Positioning
By forming new relationships, PCUBE-LAB would strengthen its position in the neurological diagnostics market, particularly in the area of eye movement biomarkers. This could enhance its reputation as a leader in innovative diagnostic technologies, potentially attracting more investors and customers.
Technology Advancements and Scaling
New relationships would likely accelerate PCUBE-LAB's technological advancements by providing access to additional expertise, resources, and data. This could lead to improved diagnostic tools and expanded capabilities in detecting neurological disorders. Additionally, partnerships with healthcare providers or pharmaceutical companies could help scale PCUBE-LAB's technology, making it more widely available and contributing to its growth in the global market.
Sources
6 The Hiring and Company Growth
PCUBE-LAB: Company Overview and Growth
PCUBE-LAB, a company based in Belgium, received EIC Accelerator funding in October 2022. However, specific details on their current team size, hiring status, and recent key positions filled are not available through the provided search results.
Current Headcount and Team Size
As of the latest available data, there is no specific information on PCUBE-LAB's current headcount or team size. For similar companies, team sizes can vary widely based on their focus and scope of operations.Hiring and Growth
While there is no direct information on whether PCUBE-LAB is currently hiring, companies that receive significant funding like the EIC Accelerator often use such support to grow their teams and scale operations. This typically involves expanding across various key positions to enhance their product offerings and market reach.Key Positions and Future Growth
New team members in companies like PCUBE-LAB typically contribute to enhancing their technological capabilities, market presence, and operational efficiency. These additions are crucial for scaling up and achieving strategic business goals. The EIC Accelerator funding is a strong indication of the company's potential for innovation and growth, suggesting that new hires will play a significant role in driving this forward.Management and Founding Team Changes
There is no available information on recent changes in PCUBE-LAB's management or founding team. However, companies that receive significant funding often undergo strategic reorganizations to align with their growing ambitions.Conclusion
PCUBE-LAB's receipt of EIC Accelerator funding marks a significant milestone in their journey, likely positioning them for substantial growth and development. While specific details on their current team and hiring status are not publicly available, the funding will likely support expanded operations and strategic hiring to drive their future success.Sources: - None specific to PCUBE-LAB could be found in the provided search results. For general information on team growth and management, see:
7 The Media Features and Publications
Overview of PCUBE-LAB
PCUBE-LAB is a cutting-edge medical technology company based in Belgium, specializing in neurological diagnostics. The company's platform focuses on extracting eye movement biomarkers to aid in the early detection of Parkinsonian syndromes. PCUBE-LAB is associated with the website p3lab.com, and its activities align with the broader scope of P3Lab SRL, a company involved in similar technological innovations.
Media Features and Publications
PCUBE-LAB has been featured in various publications for its innovative approach to neurological diagnostics using eye-tracking technology. BioWorld reported on PCUBE-LAB's $4.75 million funding round in 2021, highlighting its advancements in eye-tracking technology for diagnosing neurological disorders such as Parkinson's, multiple sclerosis, and Alzheimer's disease.
Content from Publications
Publications have noted PCUBE-LAB's development of Neuroclues, a patented pupil-frequency tagging technique. This technology is crucial for early diagnosis and has garnered significant attention in medical technology circles.
Podcasts or Interviews
There are no specific mentions of podcasts or interviews involving the team of PCUBE-LAB in the available information.
Conference and Fair Visits, Presentations or Participations
Details about specific conference participations or presentations by PCUBE-LAB are not readily available. However, the company's involvement in advancing medical technology suggests potential engagement in relevant industry events.
Involvement in Events
Given its focus on innovative medical diagnostics, PCUBE-LAB likely participates in medical technology conferences and events. Its association with EIC funding indicates involvement in European innovation ecosystems and potential participation in related events.
EIC Accelerator Funding
PCUBE-LAB received the EIC Accelerator funding in October 2022. This funding has been crucial for advancing its eye-tracking technology and expanding its market presence in Europe and beyond.
Sources: - PCUBE-LAB - European Commission
- Company - neuroClues
- Pcube-Lab raises $4.75M to advance its eye-tracking technology
- neuroClues® secures €5 million to launch its groundbreaking technology
- P³lab (SRL) - Ottignies-Louvain-la-Neuve
Do you need EIC Accelerator support?
Here is a list of the key service options for the EIC Accelerator:
Full Writing Service
All proposal sections are written by Stephan Segler, PhD.
Advisory Service
You write in-house but receive 1-on-1 support, templates, instructions, and reviews of all documents.
AI Writer & Training
A high-quality AI writer for EIC Accelerator Step 1 and a comprehensive Training program for Steps 1 and 2 including all templates and instructions.